All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Which patients with MF could benefit the most from telomerase inhibitors?

Dec 19, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in myelofibrosis.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub was pleased to speak to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, Which patients with myelofibrosis (MF) could benefit the most from telomerase inhibitors?

Which patients with MF could benefit the most from telomerase inhibitors?

Mascarenhas opens by discussing the implications for patients with MF who are unresponsive to typical JAK inhibitor therapy, considering the unmet need in this group. Mascarenhas goes on to outline the latest data from studies on telomerase inhibitors, such as imetelstat, within this patient group, with a particular focus on the increase in median survival time and eligibility for potentially curative interventions, such as stem cell transplant.